Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta‐Analysis

Abstract

Parkinson's disease (PD) biomarkers are needed by both clinicians and researchers (for diagnosis, identifying study populations, and monitoring therapeutic response). Imaging, genetic, and biochemical biomarkers have been widely studied. In recent years, extracellular vesicles (EVs) have become a promising material for biomarker development. Proteins and molecular material from any organ, including the central nervous system, can be packed into EVs and transported to the periphery into easily obtainable biological specimens like blood, urine, and saliva. We performed a systematic review and meta‐analysis of articles (published before November 15, 2022) reporting biomarker assessment in EVs in PD patients and healthy controls (HCs). Biomarkers were analyzed using random effects meta‐analysis and the calculated standardized mean difference (Std.MD). Several proteins and ribonucleic acids have been identified in EVs in PD patients, but only α‐synuclein (aSyn) and leucine‐rich repeat kinase 2 (LRRK2) were reported in sufficient studies (n = 24 and 6, respectively) to perform a meta‐analysis. EV aSyn was significantly increased in neuronal L1 cell adhesion molecule (L1CAM)–positive blood EVs in PD patients compared to HCs (Std.MD = 1.84, 95% confidence interval = 0.76–2.93, P = 0.0009). Further analysis of the biological sample and EV isolation method indicated that L1CAM‐IP (immunoprecipitation) directly from plasma was the best isolation method for assessing aSyn in PD patients. Upcoming neuroprotective clinical trials immediately need peripheral biomarkers for identifying individuals at risk of developing PD. Overall, the improved sensitivity of assays means they can identify biomarkers in blood that reflect changes in the brain. CNS‐derived EVs in blood will likely play a major role in biomarker development in the coming years. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

How close are we to a breakthrough? The hunt for blood biomarkers in Parkinson's disease diagnosis

“…It is worth noting that α-syn and p-α-syn were found on the surface of exosomes (Zheng et al, 2021), which suggested a potential role in intercellular communication or disease propagation. Similarly, a meta-analysis reached the same conclusion that NDE α-syn could distinguish PD and HC (Xylaki et al, 2023).…”

Proteomic Analysis of Salivary Extracellular Vesicles from COVID-19 Patients Reveals a Specific Anti-COVID-19 Response Protein Signature

“…Given that EVs encompass markers of the immune-inflammatory response derived both locally and systemically, they represent a potential foundation for site-specific biomarker assessments for systemic diseases in oral fluids [40][41][42]. Additionally, the diversity of EVs cargo, offering a multitude of diagnostic parameters, has the potential to enhance both sensitivity and specificity in diagnostics and the non-invasive nature of the collection of oral fluids makes the characterization and quantification of EVs, particularly in saliva, highly advantageous.…”

Biomarkers of Parkinson's disease in perspective of early diagnosis and translation of neurotrophic therapies

“…Increased quantities of total a-syn, but no change in oligomeric and phosphorylated species of a-syn, have been measured in plasma from PD patients [25]. Extracellular vesicles isolated from blood and carrying a-syn oligomers and phosphorylated a-syn may bring new possibilities for the early diagnosis of PD [26]. Blood beta-synuclein may also have relevance since, unlike a-syn, it is not present in the blood of healthy individuals [27].…”